Regulation of a graft-versus-leukemia effect by major histocompatibility complex class II molecules on leukemia cells: HLA-DR1 expression renders K562 cell tumors resistant to adoptively transferred lymphocytes in severe combined immunodeficiency mice/nonobese diabetic mice

Blood

Volumn 90, Issue 11, 1997, Pages 4553-4558

  Weichold, Frank F ^b   Jiang, Yin Zheng ^b   Dunn, Daniel E ^b   Bloom, Michael ^b   Malkovska, Vera ^b   Hensel, Nancy F ^b   Barrett, A John ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HLA DR1 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ADOPTIVE TRANSFER; ALLOGRAFT; ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CELL STIMULATION; EFFECTOR CELL; GRAFT VERSUS HOST REACTION; IMMUNE RESPONSE; KILLER CELL; LEUKEMIA CELL; LYMPHOCYTIC INFILTRATION; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; T LYMPHOCYTE SUBPOPULATION;

EID: 0030718598     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.11.4553.4553_4553_4558     Document Type: Article

References (28)

1. Butturini A, Gale RP: The role of T cells in preventing relapse in chronic myeloid leukaemia. Bone Marrow Transplant 2:351, 1987
2. Goldman JM, Gale RP, Horowitz M, Biggs JC, Champlin RK, Gluckman E, Hoffman RG, Jacobsen SJ, Marmont AM, McGlave P, Messner HA, Rimm AA, Rozman C, Speck B, Tura S, Weiner RS, Bortin MM: Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk of relapse associated with T cell depletion. Ann Intern Med 108:806, 1988
3. Van Rhee F, Kolb H-J: Donor leukocyte transfusions for leukemic relapse. Curr Opin Hematol 2:423, 1995
4. Nimer SD, Giorgi J, Gajewski JL, Ku N, Schiller GJ, Lee K, Territo M, Ho W, Feig S, Selch M, Isacescu V, Reichert TA, Champlin RE: Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. Transplantation 57:82, 1994
5. Palathumpat V, Dejbakhsh-Jones S, Strober S: The role of purified CD8+ T cells in graft-versus-leukaemia activity and engraftment after allogeneic bone marrow transplantation. Transplantation 60:355, 1995
6. Glass B, Uharek L, Zeis M, Loeffler H, Mueller-Ruchholtz W, Gassmann W: Graft-versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia cells. Br J Haematol 93:412, 1996
7. Glass B, Uharek L, Gassmann W, Focks B, Zeis M, Loeffler H, Mueller-Ruchholz W, Gassman W: Graft-versus-leukemia activity after bone marrow transplantation does not require graft-versus-host disease. Ann Hematol 64:255, 1992
8. Jiang YZ, Barrett AJ, Goldman JM, Mavroudis DA: Association of natural killer cell immune recovery with a graft-vs.-leukemia effect independent of graft vs. host disease following allogeneic bone marrow transplantation. Ann Hematol 74:1, 1997
9. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B, Truitt RL, Zwaan F, Bortin MM: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75: 555, 1990
10. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonk L, Niederwieser D, van Rhee F, Mittermuller J, de Witte T, Holler E, Ansari H: Graft versus leukemia effect of donor lymphocyte transfusion in marrow grafted patients. Blood 86:2041, 1995
11. Jiang YZ, Couriel D, Mavroudis DA, Lewalle P, Malkovska V, Hensel NF, Dermime S, Molldrem J, Barrett AJ: Interaction of NK cells with MHC class II: Reversal of HLA-DR1 mediated protection of K562 transfectant from NK cell-mediated cytolysis by brefeldin-A. Immunology 87:481, 1996
12. Shultz LD, Schweizer PA, Christianson SW, Gott B, Schweitzer IB, Tennent B, McKenna S, Mobraaten L, Rajan TV, Greiner DL, Leiter EH: Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 154:180, 1995
13. Grogg D, Hahn S, Erb P: CD4+ T-cell-mediated killing of major histocompatibility complex class-II-positive antigen-presenting cells. III. CD4+ cytotoxic T-cells induce apoptosis of APC. Eur J Immunol 22:267, 1992
14. Blazar B, Taylor P, Panoskaltsis-Mortari A, Gray GS, Vallera D: Co-blockade of the LFA-1 :ICAM and CD28/CTLA4:B7 pathway is a highly effective means of preventing acute lethal graft versus host disease induced by fully major histocompatibility complex-disparate donor grafts. Blood 85:2607, 1995
15. Gribben J, Guinan E, Boussiotis V, Ke X-Y, Linsley L, Sieff C, Gray GS, Freeman GJ, Nadler LM: Complete blockade of B7 family-mediated co-stimulation is necessary to induce human alloantigen specific anergy: A method to ameliorate graft versus host disease and extend the donor pool. Blood 87:4887, 1996
16. Kourilsky P, Claverie JM; MHC-antigen interaction: What does the T cell receptor see? Adv Immunol 45:107, 1989
17. Jiang YZ, Barrett AJ: Review-allogeneic CD4+ T cell mediated graft-versus-leukemia effect. Leuk Lymph 1997 (in press)
18. Jiang YZ, Cullis JO, Kanfer EJ, Goldman JM, Barrett AJ: T cell and NK cell mediated graft versus leukemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 11:133, 1993
19. Spits H, Lanier LL, Phillips JH: Development of human T and natural killer cells. Blood 85:2654, 1995
20. Ciccone E, Pende D, Viale O, Di Donate C, Tripodi G, Orengo AM, Guardiola J, Moretta A, Moretta L: Evidence of a natural killer (NK) cell repertoire for (Allo) antigen recognition: Definition of five distinct NK-determined allospecificities in human. J Exp Med 175:709, 1992
21. Young NT, Bunce M, Morris PJ, Welsh KI: Killer cell inhibitory receptor interactions with HLA class I molecules: Implications for alloreactivity and transplantation. Hum Immunol 52:1, 1997
22. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL: Implications for immunosurveillance of altered HLA class I phenotypes in human tumors. Immunol Today 18:89, 1997
23. Long EO, Rosren-Bronson S, Karp DR, Malnati M, Sekaly RP, Jaraquemada D: Efficient cDNA expression vector for stable and transient expression of HLA-DR1 in transfected fibroblast and lymphoid cells. Hum Immunol 31:229, 1991
24. Malkovska V, Cigel F, Storer BE: Human T cells in hu-PBLSCID mice proliferate in response to Daudi lymphoma and confer anti-tumor immunity. Clin Exp Immunol 96:158, 1994
25. Barrett AJ, Jiang YZ: Review: Immune response to chronic myeloid leukaemia. Bone Marrow Transplant 9:305, 1992
26. Dermime S, Mavroudis DA, Jiang YZ, Hensel NF, Molldrem J, Barrett AJ: Immune escape from a graft versus leukemia effect plays a role in the relapse of myelogenous leukemias following allogeneic74 bone marrow transplantation. Blood 88:610a, 1996 (abstr, suppl 1)
27. Delain M, Tiberghien P, Racadot E, Billot M, Pariset J, Chbod J, Cahn JY, Herve P: Variability of the alloreactivity T-cell response to human leukemia blasts. Leukemia 8:642, 1994
28. Ju ST, Cui H, Panka DJ, Ettinger R, Marshak-Rothstein A: Participation of target fas protein in apoptosis pathway induced by CD4+ Th1 and CD8+ cytotoxic T cells. Proc Natl Acad Sci USA 91:4185, 1994